This Article Full Text Full Text (PDF) Other Versions of this Article: CVI.00310-07v1 15/2/314    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gilderman, L. I. Search for Related Content PubMed PubMed Citation Articles by Gilderman, L. I.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2008, p. 314-319, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00310-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax

University Clinical Research, Pembroke Pines, Florida,¹ FFM Clinical Research, Camillus, New York,² Tomac, Inc., Columbiana, Alabama,³ Infectious Disease/Vaccine Clinical Research, Merck & Co., Inc., West Point, Pennsylvania,⁴ Medical Communications, Merck & Co., Inc., West Point, Pennsylvania,⁵ Clinical Biostatistics, Merck & Co., Inc., West Point, Pennsylvania⁶

Received 27 July 2007/ Returned for modification 11 September 2007/ Accepted 21 November 2007

The vaccine Zostavax has been shown to prevent herpes zoster (HZ) and postherpetic neuralgia and is recommended for individuals 60 years of age. This study compared the safety and the immunogenicity of a refrigerator-stable formulation (Zostavax refrigerated) with those of the current formulation (Zostavax frozen) in subjects 50 years of age. Subjects with a negative history for HZ were randomized 1:1 to receive one dose of either formulation. Enrollment was stratified 1:2 by age (50 to 59 years and 60 years). Safety was evaluated for 28 days postvaccination. Varicella-zoster virus (VZV) antibody responses were measured by a glycoprotein enzyme-linked immunosorbent assay (gpELISA). The primary endpoints were the VZV antibody geometric mean titer (GMT; day 28), the VZV antibody geometric mean rise (GMR; days 1 to 28), and the incidence of vaccine-related serious adverse experiences (AEs) over 28 days. The refrigerated (n = 182) and frozen (n = 185) formulations induced similar GMTs (727.4 and 834.4 gpELISA units/ml, respectively); the estimated GMT ratio (refrigerated formulation/frozen formulation) was 0.87 (95% confidence interval, 0.71 to 1.07). The GMRs were 2.6- and 2.9-fold, respectively. No vaccine-related serious AEs were reported in either group, and the safety profiles of the formulations were generally similar. The frequencies of injection-site AEs during follow-up were 35.6% and 46.4% in the refrigerated and the frozen formulation groups, respectively, and were generally mild. The frequencies of systemic AEs were similar in the two groups, and those of vaccine-related AEs were 6% in both groups. The refrigerator-stable formulation of Zostavax has an acceptable safety profile and is as immunogenic as the frozen formulation; thus, the vaccine may be used in clinical settings where freezer availability is limited.

Published ahead of print on 12 December 2007.